Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes

Dystonia Clinical Trial

— SensoMo-PD  

Official title:

SensoMo-PD: Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05713721
• Other study ID #: MJFF-022062
• Status: Recruiting
• Start date: January 1, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: June 2023
• Source: University Hospital Schleswig-Holstein
• Contact: Anne Weissbach, MD
• Phone: +49 451 3101 8219
• Email: anne.weissbach[@]neuro.uni-luebeck.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hereditary Parkinson and dystonia syndromes are rare, as are people who carry the predisposition for Parkinson or dystonia but do not have symptoms. It is particularly important to study these people because they are a good model for understanding the development of common non-hereditary Parkinson's and dystonia. To do this, the investigators want to look at how the brain works and how different areas of the brain communicate with each other. The investigators want to identify differences in brain regions connecting perception and action between mutation carriers that develop clinical symptoms and those who stay healthy in different subgroups of inherited Parkinson-dystonia syndromes. Mutation carriers with and without symptoms of three different inherited Parkinson-dystonia syndromes will be investigated at their homes with the help of a mobile examination unit. To detect even subtle signs, which the mutation carriers might not even be aware of, the investigators will use a detailed video-based and -documented movement examination and a non-invasive magnetic stimulation technique that investigates how a sensory, i.e., electrical stimulus can influence the motor response in a hand muscle. Our study will allow the investigators, on the one hand, to define specific markers that protect some mutation carriers from having clinical symptoms and, on the other hand, to identify neurophysiological characteristics that all mutation carriers share whether or not they have clinical symptoms. These are important information for a better understanding of the basis of these disorders and for the development of new treatment strategies, which can also be transferred to genetically-undefined Parkinson's and dystonia syndromes. Through this study, large groups of mutation carriers that have received an in-depth clinical and neurophysiological examination and can be investigated longitudinally in future studies will be build up.

Description:

Monogenic Parkinson-dystonia syndromes are rare but very valuable model disorders for genetically undefined syndromes, as their genetic cause, i.e., pathogenic gene variants, have been identified. For certain subtypes, even the neuroanatomical basis was discovered. Despite the different genetic and anatomical characteristics, a strong clinical overlap was reported between PARK-Parkin/PARK-PINK1, DYT/PARK-GCH1, and DYT/PARK-TAF1.

Interestingly, previous research in these different Parkinson-dystonia syndromes suggests a distinct pattern of neurophysiological alterations within the primary motor and premotor-motor network for each syndrome. Even asymptomatic, heterozygous mutation carriers, show abnormalities within neurophysiological and in addition, functional, metabolic, and structural imaging studies.

In general, a better clinical and neurophysiological evaluation of asymptomatic compared to symptomatic mutation carriers and healthy controls across subgroups is warranted. However, the number of mutation carriers per subgroup is limited and some are unable to travel to Lübeck to participate in research. To increase the participant size, in addition to the examination in our neurophysiological laboratory, the investigators want to visit and investigate some mutation carriers in their home environment with a mobile examination unit. In this regard, the transcranial magnetic stimulation paradigm of short-latency afferent inhibition (SAI) is of great interest as it can reliably capture the effects of sensory input (median nerve stimulation) on motor output (MEP amplitude) without complex neuronavigation. Additionally, a video-based clinical examination will be performed, which will be rated offline in a blinded fashion by movement disorder specialists to correlate SAI with symptom severity.

Therefore, the proposed project will, for the first time, allow a direct comparison of sensorimotor integration deficits in correlation to clinical signs between three different monogenic Parkinson-dystonia syndromes. Furthermore, contrasting the findings between asymptomatic and symptomatic mutation carriers will help, on the one hand, to draw conclusions on potential protective markers, and on the other hand, to identify neurophysiological endophenotypes. Furthermore, successful completion of the project will generate clinically well-defined monogenic subgroups with particular sensorimotor abnormalities, who can serve as model disorders in further research projects that aim to characterize sensorimotor deficit in a cognitive framework and in a longitudinal fashion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 31, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion criteria for mutation carriers:

• Pathogenic Parkin, PINK1, GCH1, or TAF1 gene variant

• Age >18 years

• Informed consent

Inclusion criteria for healthy control participants:

• No movement disorder

• Age >18 years

• Informed consent

• No medication with influences on the central nervous system

Exclusion Criteria:

• Age <18 years

• Pregnancy

• Epilepsy

• Medication that reduces the seizure threshold

Related Conditions & MeSH terms

• Dystonia
• Dystonia, Familial
• Dystonic Disorders
• Parkinson
• Parkinson Disease

Intervention

Device:
• Transcranial magnetic stimulation (TMS)
TMS over the left primary motor cortex will be performed. To investigate sensorimotor integration, an electrical stimulus on the right index finger will precede the TMS pulse.

Other:
• Video-based clinical examination
A standardized neurological examination will be performed and video taped. The videos will be rated by movement disorder specialists, wo are blinded for the symptom and mutation status of the participants.
• 24 hours drug withdrawal of dopaminergic medication
Examinations will be done under chronic dopaminergic treatment and after a 24 hours dopaminergic drug withdrawal.
• Evaluation of deep brain stimulation
Examinations will be done before and after implantation of deep brain stimulation (clinically optimal stimulation vs. switched off stimulation)

Locations

Country	Name	City	State
Germany	Institute of Systems Motor Science Lübeck	Lübeck	Schleswig-Holstein

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Schleswig-Holstein	Michael J. Fox Foundation for Parkinson's Research

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Contrast sensorimotor integration in patients with three different monogenic Parkinson-dystonia syndromes.	Transcranial magnetic stimulation (short-latency afferent inhibition)	Two timepoints (if applicable): With chronic dopaminergic medication vs. 24h drug withdrawal OR before and after deep brain stimulation implantation
Primary	Define whether asymptomatic mutation carriers show abnormalities in sensorimotor integration and clinical signs of Parkinson and dystonia upon video examination.	Video based clinical examination	One timepoint
Primary	Correlate clinical symptom severity with changes in sensorimotor integration.	Transcranial magnetic stimulation (short-latency afferent inhibition) and Video based clinical examination	Two timepoints (patients) or one timepoint (asymptomatic mutation carriers and healthy control participants)
Primary	Evaluate treatment effects on sensorimotor integration, e.g., for PARK-Parkin/PARK-PINK1 and DYT/PARK-GCH1 chronic dopaminergic medication and for DYT/PARK-TAF1 deep brain stimulation effects.	Transcranial magnetic stimulation (short-latency afferent inhibition)	Two timepoints (if applicable): With chronic dopaminergic medication vs. 24h drug withdrawal OR before and after deep brain stimulation implantation